Treating cancer with selective CDK4/6 inhibitors (Q38794109)

6 September 2017

Treating cancer with selective CDK4/6 inhibitors (English)

1 reference

6 September 2017

1

0 references

author name string

Richard S Finn

series ordinal

2

1 reference

PubMed ID

27030077

6 September 2017

Nicholas C Turner

series ordinal

3

1 reference

PubMed ID

27030077

6 September 2017

language of work or name

English

0 references

publication date

31 March 2016

1 reference

Nature Reviews Clinical Oncology

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

417-430

1 reference

6 September 2017

7

1 reference

Genetic control of the cell division cycle in yeast

6 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cell-cycle checkpoints and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cell cycle, CDKs and cancer: a changing paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cell cycle kinases as therapeutic targets for cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The history and future of targeting cyclin-dependent kinases in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Nobel Lecture. Cyclin dependent kinases and cell cycle control.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin D1 is a nuclear protein required for cell cycle progression in G1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK inhibitors: positive and negative regulators of G1-phase progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Identification of G1 kinase activity for cdk6, a novel cyclin D partner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Retinoblastoma protein switches the E2F site from positive to negative element

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Mechanism of active transcriptional repression by the retinoblastoma protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Association of cdk2 Kinase with the Transcription Factor E2F During S Phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The retinoblastoma protein is phosphorylated during specific phases of the cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The retinoblastoma tumour suppressor in development and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Rb interacts with histone deacetylase to repress transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p16INK4 mediates contact-inhibition of growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Mutations and altered expression of p16INK4 in human cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p27KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Interaction between Cdc37 and Cdk4 in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Growth suppression by p16ink4 requires functional retinoblastoma protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Inhibition of cyclin-dependent kinases by p21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

New functional activities for the p21 family of CDK inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Proliferation of cancer cells despite CDK2 inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cdk1 is sufficient to drive the mammalian cell cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin C/cdk3 promotes Rb-dependent G0 exit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The requirement for cyclin D function in tumor maintenance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Requirement for CDK4 kinase function in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Distinct sets of genetic alterations in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The somatic genomic landscape of glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Sequencing of t(2;7) translocations reveals a consistent breakpoint linking CDK6 to the IGK locus in indolent B-cell neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5(-) monoclonal B-cell lymphocytosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Translocation t(2;7)(p11;q21) associated with the CDK6/IGK rearrangement is a rare but recurrent abnormality in B-cell lymphoproliferative malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Frequency of homozygous deletion at p16/CDKN2 in primary human tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

An integrated genomic analysis of human glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Germline p16 mutations in familial melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin D as a therapeutic target in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Repeated observation of breast tumor subtypes in independent gene expression data sets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Comprehensive molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

RB in breast cancer: at the crossroads of tumorigenesis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Targeting cell cycle and hormone receptor pathways in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Specific protection against breast cancers by cyclin D1 ablation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Treatment of growing teratoma syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

PD0332991 (palbociclib) for treatment of pediatric intracranial growing teratoma syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Tamoxifen-stimulated growth of breast cancer due to p21 loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.26

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining

31 March 2020

1 reference

12 December 2020

Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck

1 reference

12 December 2020

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue

1 reference

12 December 2020

Saccharomyces cerevisiae cell cycle

1 reference

12 December 2020

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity

1 reference

12 December 2020

Amplification and expression of the human cyclin D gene in esophageal cancer

1 reference

12 December 2020

PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma

1 reference

12 December 2020

Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.

1 reference

12 December 2020

From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner?

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

1 reference

12 December 2020

PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas

1 reference

12 December 2020

Rb and p16INK4a expression in resected non-small cell lung tumors.

1 reference

12 December 2020

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

1 reference

12 December 2020

10.1038/NRCLINONC.2016.26

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27030077